Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levomethadone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 0.97 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.97 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.97 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.97 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.97 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.97 |
| ▸ | DRD3 | P35462 | 3/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.97 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.97 |
| ▸ | DRD4 | P21917 | 2/20 | 0.97 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.97 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.97 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.97 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.97 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.97 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.97 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.97 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methadone SCHEMBL5486844 | 1.00 | GRIN1 (0.97) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Methadone SCHEMBL1369177 | 1.00 | GRIN1 (0.97) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Methadone SCHEMBL7107052 | 1.00 | GRIN1 (0.97) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Methadone SCHEMBL3426247 | 1.00 | GRIN1 (0.97) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Esmethadone SCHEMBL6055296 | 1.00 | GRIN1 (0.97) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Methadone SCHEMBL24293 | 1.00 | GRIN1 (0.97) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Methadone SCHEMBL18321925 | 1.00 | GRIN1 (0.97) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Methadone SCHEMBL23589519 | 0.98 | GRIN1 (0.94) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Methadone SCHEMBL8988558 | 0.98 | GRIN1 (0.94) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C | |
| Methadone SCHEMBL2855175 | 0.98 | GRIN1 (0.94) | GRIN1GRIN2AOPRM1GRIN2DGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4473961-A1 | ORAL SOLID PHARMACEUTICAL FORMULATION COMPRISING METHADONE/LEVOMETHADONE AND OPTIONALLY NALOXONE | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO S.p.A. (IT) | 2024-12-11 | — | — | EP | claimed |
| US-11332434-B2 | Synthesis of levomethadone hydrochloride | SAFAEI GHOMI JAVAD (IR) | 2022-05-17 | — | — | US | claimed |
| WO-2020212890-A1 | SYNTHESIS OF LEVOMETHADONE HYDROCHLORIDE | SAFAEI GHOMI JAVAD (IR) | 2020-10-22 | — | — | WO | claimed |
| US-20200277250-A1 | SYNTHESIS OF LEVOMETHADONE HYDROCHLORIDE | SAFAEI GHOMI JAVAD (IR) | 2020-09-03 | — | — | US | claimed |
| US-20190002394-A1 | SYNTHESIS OF LEVOMETHADONE HYDROCHLORIDE OR DEXTROMETHADONE HYDROCHLORIDE AND METHODS FOR USE THEREOF | CODY LABORATORIES, INC. | 2019-01-03 | — | — | US | claimed |
| US-10040752-B2 | Synthesis of levomethadone hydrochloride or dextromethadone hydrochloride and methods for use thereof | CODY LABORATORIES, INC. (US) | 2018-08-07 | — | — | US | claimed |
| EP-3341354-A1 | SYNTHESIS OF LEVOMETHADONE HYDROCHLORIDE OR DEXTROMETHADONE HYDROCHLORIDE AND METHODS FOR USE THEREOF | Cody Laboratories, Inc. (US) | 2018-07-04 | — | — | EP | claimed |
| US-20170349534-A1 | A NOVEL PROCESS FOR CHIRAL RESOLUTION OF HIGHLY PURE (6R)-6-(DIMETHYLAMINO)-4,4-DIPHENYL-HEPTANONE FROM RACEMIC METHADONE HYDROCHLORIDE | HARMAN FINOCHEM LIMITED (IN) | 2017-12-07 | — | — | US | claimed |
| EP-3237373-A1 | \"A NOVEL PROCESS FOR CHIRAL RESOLUTION OF HIGHLY PURE (6R)-6-(DIMETHYLAMINO)-4,4-DIPHENYL-3-HEPTANONE FROM RACEMIC METHADONE HYDROCHLORIDE\ | Harman Finochem Limited (IN) | 2017-11-01 | — | — | EP | claimed |
| WO-2017035224-A1 | SYNTHESIS OF LEVOMETHADONE HYDROCHLORIDE OR DEXTROMETHADONE HYDROCHLORIDE AND METHODS FOR USE THEREOF | CODY LABORATORIES, INC. (US) | 2017-03-02 | — | — | WO | claimed |
| US-20170057909-A1 | SYNTHESIS OF LEVOMETHADONE HYDROCHLORIDE OR DEXTROMETHADONE HYDROCHLORIDE AND METHODS FOR USE THEREOF | ALTER DOMUS (US) LLC | 2017-03-02 | — | — | US | claimed |
| WO-2016103274-A1 | \"A NOVEL PROCESS FOR CHIRAL RESOLUTION OF HIGHLY PURE (6R)-6-(DIMETHYLAMINO)-4,4-DIPHENYL-3-HEPTANONE FROM RACEMIC METHADONE HYDROCHLORIDE\ | HARMAN FINOCHEM LIMITED (IN) | 2016-06-30 | — | — | WO | claimed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| EP-4473961-A1 | ORAL SOLID PHARMACEUTICAL FORMULATION COMPRISING METHADONE/LEVOMETHADONE AND OPTIONALLY NALOXONE | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO S.p.A. (IT) | 2024-12-11 | — | — | EP | disclosed |
| US-20240335400-A1 | GASTRIC RESIDENCE SYSTEMS COMPRISING METHADONE | Nortiva Bio, Inc. | 2024-10-10 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| EP-0907388-A1 | PHARMACEUTICAL ADMINISTRATION FORM | Müller, Dieter (DE) | 1999-04-14 | — | — | EP | disclosed |
| EP-0834309-A2 | Use of a liposome solution for enhancing the activity and/or reducing the toxicity of drugs | Mesmer, Artur Herzog, Dr. (DE) | 1998-04-08 | — | — | EP | disclosed |
| WO-1998000198-A1 | PHARMACEUTICAL ADMINISTRATION FORM | MUELLER DIETER (DE) | 1998-01-08 | — | — | WO | disclosed |
| US-4070494-A | Enteral pharmaceutical compositions | BAYER AKTIENGESELLSCHAFT (DT) | 1978-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349534-A1 | A NOVEL PROCESS FOR CHIRAL RESOLUTION OF HIGHLY PURE (6R)-6-(DIMETHYLAMINO)-4,4-DIPHENYL-HEPTANONE FROM RACEMIC METHADONE HYDROCHLORIDE | OPRK1, OPRM1, CYP2D6 | OPRM1 2/4885GRIN1 1001/4885GRIN2A 838/4885 |
| US-20170057909-A1 | SYNTHESIS OF LEVOMETHADONE HYDROCHLORIDE OR DEXTROMETHADONE HYDROCHLORIDE AND METHODS FOR USE THEREOF | CYP2D6, COMT, AADAT | OPRM1 35/4885GRIN1 1976/4885GRIN2A 755/4885 |
| US-20190002394-A1 | SYNTHESIS OF LEVOMETHADONE HYDROCHLORIDE OR DEXTROMETHADONE HYDROCHLORIDE AND METHODS FOR USE THEREOF | CYP2D6, COMT, AADAT | OPRM1 35/4885GRIN1 1976/4885GRIN2A 755/4885 |
| US-10040752-B2 | Synthesis of levomethadone hydrochloride or dextromethadone hydrochloride and methods for use thereof | CYP2D6, COMT, AADAT | OPRM1 35/4885GRIN1 1976/4885GRIN2A 755/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | OPRM1 1737/4885GRIN1 3406/4885GRIN2A 2892/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | OPRM1 2373/4885GRIN1 2511/4885GRIN2A 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.